¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Kaplan-Meier survival curve, method"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival curve
    »ýÁ¸°î¼±
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival
    »ýÁ¸
  • survival analysis
    »ýÁ¸ºÐ¼®
  • survival function
    »ýÁ¸ÇÔ¼ö
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
  • survival time
    »ýÁ¸±â°£
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival curve
    »ýÁ¸°î¼±
  • curve
    °î¼±
  • epidemic curve
    À¯Çà°î¼±
  • learning curve
    ÇнÀ°î¼±
  • regression curve
    ȸ±Í°î¼±
  • response curve
    ¹ÝÀÀ°î¼±
  • method of experiment
    ½ÇÇè¹æ¹ý
  • method
    ¹æ¹ý, ¹ý
  • analytical method
    ºÐ¼®¹ý
  • blind method
    ´«°¡¸²¹ý
  • projective method
    Åõ»ç¹ý
  • reflection method
    ¹Ý»ç¹ý
  • survival analysis
    »ýÁ¸ºÐ¼®
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival curve
    »ýÁ¸°î¼±
  • survival analysis
    »ýÁ¸ºÐ¼®
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • disease free survival
    ¹«º´»ýÁ¸
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • forward survival
    ÇâÈÄ»ýÁ¸
  • survival function
    »ýÁ¸ÇÔ¼ö
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í°Ë»ç
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • survival rate
    »ýÁ¸À²
  • survival ratio
    »ýÁ¸ºñ
  • survival ration
    ±¸¸í½Ä·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • probability of survival
    »ýÁ¸(È®)·ü(Ë×Ì¡ Ì·Ëô).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • AUC : area under the concentration-time curve
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • Hemoglobin-oxygen equilibrium curve
    Çì¸ð±Û·Îºó-»ê¼Ò°î¼±
  • Length/tension curve
    ±æÀÌ/Àå·Â(íåÕô) °î¼±(ÍØàÊ)
  • area under the concentration-time curve : AUC
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • frequency curve
    µµ¼ö°î¼±(̬ËàË­ËÛ).
  • frequency curve
    µµ¼ö°î¼±
  • frequency distribution curve
    µµ¼öºÐÆ÷°î¼±.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • survival curve
    »ýÁ¸°î¼±(ßæðíÍØàÊ).
  • survival curve
    »ýÁ¸°î¼±(ßæðíÍØàÊ)
  • life-table method of survival estimation
    »ý¸íÇ¥¹ý(»ýÁ¸ ÃßÁ¤ ¹æ¹ý)
  • carbol fuchsin method ; Ziehl-Neelsen method
    Ä«¸£º¼ Ç«½Å¹ý; Áú-´ÏÀϼ¾¹ý ¡ìÇ׻꼺¿°»ö¹ý¡í.
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • combat survival
    ÀüÅõ»ýÁ¸(¡­ßæðí).
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • desert survival
    »ç¸·»ýÁ¸(Ë×ËÎË×Ì¡).
  • disease free survival
    ¹«º´»ýÁ¸
  • erythrocyte survival
    ÀûÇ÷±¸»ýÁ¸
  • five year survival rate
    5³â»ýÁ¸À².
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • brine flotation method
    ½Ä¿°¼öºÎÀ¯¹ý
  • crushing method
    ÆÄ°¢¹ý
  • dilution egg counting method
    Èñ¼®Ãæ¶õ°è»ê¹ý
  • natural emerging method
    ÀÚ¿¬À¯Ãâ¹ý
  • squash method
    ¾ÐÂø¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • exponential survival curve
    Áö¼ö »ýÁ¸ °î¼± (ò¦â¦ßæðíÍØàÊ)
  • survival curve
    »ýÁ¸°î¼± (ßæðíÍØàÊ)
  • calibration curve
    "°ËÁ¤°î¼±(ËþïÒÍØàÊ), Ç¥Áذ(øöñÞÍØàÊ)"
  • Cot curve
    Cot °î¼±(ÍØàÊ)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • error curve
    ¿ÀÂ÷ °î¼± (è¦ó¬ÍØàÊ)
  • exponential curve
    Áö¼ö °î¼± (ò¦â¦ÍØàÊ)
  • fall curve
    °¨¼Ò °î¼± (Êõá´ÍØàÊ)
  • Gaussian error curve
    °¡¿ì½º ¿ÀÂ÷ °î¼±(è¦ó¬ ÍØàÊ)
  • gradient curve
    ±¸¹è °î¼±(ÎþÛÕÍØàÊ)
  • growth curve
    ¼ºÀå°î¼± (à÷íþÍØàÊ)
  • hydrogen ion titration curve
    ¼ö¼Ò(â©áÈ)À̿ ÀûÁ¤°î¼±(îêïÒÍØàÊ)
  • melting curve
    À¶Çذ(ë×ú°ÍØàÊ)
  • oxygen dissociation curve
    »ê¼ÒÇØ¸®°î¼±(ß«áÈú°×îÍØàÊ)
  • oxygen saturation curve
    »ê¼ÒÆ÷È­°î¼±(ß«áÈøéûúÍØàÊ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival
    »ýÁ¸
  • curve
    °î¼±
  • dissociation curve
    ÇØ¸®°î¼±
  • elastic curve
    ź¼º°î¼±
  • exponential curve
    Áö¼ö°î¼±
  • fluid velocity curve
    À¯¼Ó°î¼±
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±
  • isodose curve
    µî¼±·®°î¼±
  • phase curve
    À§»ó°î¼±
  • time compensation curve
    ½Ã°£º¸»ó°î¼±
  • time gain compenstaion curve
    ½Ã°£°ÔÀκ¸»ó°î¼±
  • time motion curve
    ½Ã°£¿îµ¿°î¼±
  • acquisition method
    ȹµæ¹æ¹ý
  • bolus-tracking method
    µ¢¾î¸®ÃßÀû¹æ¹ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FTC Federal Trade Commission; follicular thyroid carcinoma; frequency threshold curve; frequency tuning ...
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
HI Method Hemagglutination Inhibiting Method; Ç÷±¸ ÀÀÁý ¾ïÁ¦¹ý
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BEM Boundary Elements Method
CAM Confusion Assessment Method
CRM Continual Reassessment Method
FEM Finite Element Method
HPLC High-Performance Liquid Chromatographic method
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • jungle survival
    Á¤±Û »ýÁ¸
  • survival
    »ýÁ¸
  • survival rate
    »ýÁ¸À²
  • angular spectrum envelope curve
    ?
  • anodic polarization curve
    ¾ç±Ø Æí±¤ °î¼±, ¾ç±Ø ºÐ±Ø °î¼±
  • anteroposterior curve
    ÀüÈÄ ¸¸°î
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • auditory sensation curve
    °¡Ã» °î¼±
  • Barnes' curve
    ¹Ù¾È½º °î¼±
    õ°ñ°©°¢À» Áß½ÉÀ¸·Î ÇÏ´Â °î¼±.
  • calibration curve
    º¸Á¤ °î¼±, Ç¥ÁØÈ­ °î¼±
  • carbon dioxide dissociation curve
    ź»ê °¡½º ÇØ¸® °î¼±
  • compensating curve
    Á¶Àý ¸¸°î
    »ó¾Ç Ä¡¿­¿¡ À־ ¼Ò±¸Ä¡ ´ë±¸Ä¡ÀÇ ÇùÃø ±³µÎ¸éÀ» ¿¬°áÇϸé, ¾Æ·¡·Î º¼·ÏÇÑ °î¼±À» ±×¸®°í ÀÖ´Ù. ÀÌ ¸¸°î¿¡ ÀÇÇÏ¿© ÇϾÇÀÇ Ãø¹æ ¿îµ¿ ½Ã¿¡ °úµÎ°¡ ÀüÇϹæÀ¸·Î ¿îµ¿ÇÏ´õ¶óµµ »óÇÏ Ä¡¾ÆÀÇ ±ÕÇü Á¢ÃËÀº À¯ÁöµÇµµ·Ï Á¶ÀýµÈ´Ù. °¡·É »óÇÏÀÇ Ä¡¾Æ°¡ Æò¸é»ó¿¡ ¹è¿­Çß´Ù°í ÇÑ´Ù¸é, Ãø¹æ ¿îµ¿¿¡ ÀÇÇÏ¿© °úµÎ´Â »ç¸é¿¡ µû¶ó ÀüÇϹæÀ¸·Î À̵¿ÇϹǷÎ, ´ë±¸Ä¡ ¹× ¼Ò±¸Ä¡¿¡¼­ »óÇÏ Ä¡¾Æ »çÀÌ¿¡ Æ´ÀÌ »ý±ä´Ù. À̰ÍÀ» ÆòźÇÑ Ä¡¾ÆÀÇ ¿îµ¿°ú ºñ½ºµëÇÑ ±³µÎÀÇ ¿îµ¿¸é°úÀÇ »çÀÌ¿¡ ºÒ±ÕÇüÀÌ »ý±â±â ¶§¹®ÀÌ´Ù. ±×·¯¹Ç·Î ¸¸°î¸é »ó¿¡ Ä¡¾Æ¸¦ ¹è¿­ÇÑ´Ù. ÀÌ ¿ë¾î´Â ÀÇÄ¡¿¡ ÇÑÇÏ¿© »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹´Ù.
  • concentration-response curve
    ³óµµ ¹ÝÀÀ °î¼±
  • curve of dental cervical line
    Ä¡°æ ¼± ¸¸°î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
median survival <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median.
(16 Dec 1997)
cell survival The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
(12 Dec 1998)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
survival 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving.
2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest.
<biology> See Natural selection, under Natural.
Origin: From Survive.
Source: Websters Dictionary
(01 Mar 1998)
survival analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
(12 Dec 1998)
survival rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
(12 Dec 1998)
survival time The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells.
(05 Mar 2000)
disease-free survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
(12 Dec 1998)
tissue survival The span of viability of a tissue or an organ.
(12 Dec 1998)
five year survival rate The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
long-term survival <oncology> Term used to describe the survival of leukaemia patients who have been disease free for prolonged periods of time, usually at least five years. The chance of disease returning (relapse) decreases with time.
(13 Nov 1997)
active length-tension curve The relationship between active isometric tension and preload (rest length) for a contracting muscle.
(05 Mar 2000)
alignment curve The line passing through the centre of the teeth laterally in the direction of the curve of the dental arch.
(05 Mar 2000)
anti-Monson curve In dentistry, a curve of occlusion which is convex upward.
Synonym: anti-Monson curve.
(05 Mar 2000)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
Kaplan-Meier survival curve, method see under curve and method.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival
    »ì¾Æ ³²À½
  • survival
    ÀÜÁ¸;»ì¾Æ³²À½;»ýÁ¸ÀÚ;ÀÜÁ¸¹°;¿¹ºÎÅÍÀÇ Ç³½À(½Å¾Ó)
  • curve
    ±¸ºÎ¸®´Ù
  • French curve
    ¿îÇüÀÚ
  • characteristic curve
    Ư¼º °î¼±
  • curve
    °î¼±;(¿©ÀÚÀÇ ¸ö.µµ·Î µîÀÇ)¸¸°îºÎ;±¼°î;(¿©ÀÚÀÇ)°î¼±¹Ì;±¸ºÎ··ÀÌ;°î¼±ÀÚ;°î¼± µµÇ¥;±×·¡ÇÁ;°î¼±;Ä¿ºê(°ø);Ä¿ºê Æò°¡;»ó´ë Æò°¡;±ÁÈ÷´Ù;¸¸°î½ÃŰ´Ù;(°øÀ»)Ä¿ºê½ÃŰ´Ù;±¸ºÎ·¯Áö´Ù;¸¸°îÇÏ´Ù;°î¼±À» ±×¸®´Ù
  • curve killer
    ¿ìµî»ý
  • distribution curve
    (Åë°è)ºÐÆ÷ °î¼±
  • hanging curve
    Çà°Å Ä¿ºê(±¸ºÎ·¯ÁöÁö ¾ÊÀº Ä¿ºê·Î,¶§¸®±â ÁÁÀº °øÀÌ µÊ)
  • howgozit curve
    (ƯÈ÷ ´ë¾çȾ´Ü Ç×°øÁßÀÇ)»óȲ ÆÇ´Ü °î¼±
  • indifference curve
    (°æ) ¹«Â÷º°°î¼±
  • phillips curve
    Çʸ³½ºÄ¿ºê;ÀÎÇ÷¹¿Í ½Ç¾÷·ùÀÇ »ó°ü °ü°è¸¦ ³ªÅ¸³¿
  • response curve
    (¸¶ÀÌÅ©·ÎÆùµîÀÇ)ÀÀ´ä °î¼±
  • chief method
    ÁÖ¿ä ¼ö´Ü
  • method
    ¹æ¹ý,¼ø¼­,¹æ½Ä
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á